The Future of HEOR: Moving Beyond Static Deliverables

“The next era of HEOR will not be defined by static evidence deliverables. It will be defined by continuously learning evidence engines that keep pace with an increasingly dynamic healthcare environment.”

A Profession at an Inflection Point

For decades, health economics and outcomes research (HEOR) has played a critical role in supporting evidence-based decision-making across healthcare systems. Literature reviews, indirect treatment comparisons, economic models, value dossiers, and HTA submissions have become foundational to demonstrating value and informing access decisions.

Yet the environment in which these deliverables are created and used has changed dramatically. Evidence is evolving continuously, treatment landscapes are becoming more complex, real-world data sources are expanding, and payers and HTA agencies are demanding increasingly sophisticated demonstrations of value. Despite these changes, many HEOR workflows remain largely episodic, producing evidence at fixed time points rather than maintaining it as new information emerges.

We believe that model is approaching its limits.

The future of HEOR will not be defined by better static deliverables. It will be defined by better systems for maintaining, synthesizing, and applying evidence.

The Growing Challenge of Evidence

The challenge facing the industry today is no longer simply generating evidence; it is keeping pace with it.

Every year brings thousands of new publications, conference presentations, real-world evidence studies, economic evaluations, and comparative effectiveness analyses. At the same time, treatment pathways are becoming increasingly personalized, pricing pressures are intensifying, and healthcare systems are navigating rapidly evolving policy priorities, regulatory expectations, and global evidence requirements.

The issue is not simply the growing volume of information, but the expectation that organizations can rapidly translate it into evidence that is relevant, credible, and decision–ready.

As both the volume of information and the demands placed on evidence continue to grow, the traditional model of developing static evidence assets with periodic update cycles becomes increasingly difficult to sustain. A systematic literature review completed today may require revision within months; economic models may need to incorporate new clinical evidence, comparator data, pricing assumptions, or policy changes long before their next formal update cycle; even value propositions developed at launch often require continuous refinement as evidence, market conditions, and decision-maker expectations evolve.

The question is no longer whether organizations can generate evidence, but whether they can continuously maintain, synthesize, and apply it.

Why AI Changes the Equation

This is where artificial intelligence could fundamentally reshape HEOR. Although much of the current discussion around AI focuses on productivity gains, the larger opportunity is far more transformative: shifting evidence generation from a sequence of disconnected projects into a continuously evolving evidence ecosystem in which evidence can be monitored, synthesized, updated, and applied as new information emerges.

Imagine continuous literature surveillance, evidence syntheses that can be updated as new studies are published, economic models that can be adapted more efficiently as assumptions change. Evidence gaps could be identified proactively rather than retrospectively. Evolving HTA requirements could be incorporated into evidence-generation strategies before they become barriers.

Importantly, none of this diminishes the importance of scientific expertise. As information becomes more abundant and decision-making becomes more complex, expert interpretation and judgement become even more valuable. The choice is not human expertise or AI. The future of HEOR lies in human expertise amplified by AI.

“The opportunity is not to replace experts, but to enable experts to operate at a scale and speed that has never before been possible.”

From Static Deliverables to Evidence Management

This is the direction we believe the future of HEOR is heading.

Increasingly, organizations need evidence to function as a continuously evolving strategic asset rather than a series of individual static outputs.

This requires connecting evidence planning, literature reviews, evidence synthesis, indirect treatment comparisons, economic modeling, real-world evidence, publication strategy, value demonstration, and HTA readiness.

AI can support this model by monitoring emerging evidence, identifying gaps, prioritizing analyses, and surfacing insights as information evolves. The conversation then shifts from requesting individual deliverables to answering more strategic questions:

  • What has changed in the evidence landscape?
  • Where are the most important evidence gaps?
  • How does new evidence affect reimbursement risk?
  • What should we do next?

That shift from project delivery to continuous evidence management has the potential to fundamentally redefine how HEOR creates value.

Beyond HEOR

The implications extend far beyond HEOR.

Evidence increasingly influences decisions across development, medical affairs, market access, pricing, and commercialization. Yet these activities have often operated through separate teams, technologies, and workflows. As evidence becomes more dynamic and decision-making becomes more interconnected, organizations will need approaches that connect evidence creation, evidence management, and decision-making more seamlessly.

Why We’re Optimistic

The future of HEOR will continue to be grounded in the scientific rigor that has defined the field for decades. Literature reviews, evidence synthesis, economic modeling, real-world evidence, and HTA submissions will remain foundational capabilities.

What may change is how these capabilities are connected.

As evidence volumes grow and decision-making becomes more complex, organizations will increasingly need to generate, maintain, and apply evidence across the product lifecycle. AI and advanced technologies can support this evolution by helping teams keep evidence current, identify emerging risks, and generate insights faster than ever before.

Technology alone will not drive this transformation. Its value will depend on scientific expertise, human judgment, therapeutic knowledge, and an understanding of the needs of healthcare decisionmakers.

The greatest opportunities will come from combining these strengths with technology in ways that enhance, rather than replace, the science.

What excites our team most about the future of HEOR is not simply the prospect of producing evidence more efficiently. It is the opportunity to transform evidence from a series of static deliverables into a dynamic strategic asset that informs better decisions across the healthcare ecosystem.

Author
Chris Cameron headshot
Chris Cameron, PhD
Senior Vice President, Data Analytics & Evidence Synthesis

Dr. Chris Cameron is a global thought leader in health economics and outcomes research with over a decade of experience. Prior to joining EVERSANA, Chris was a partner at Cornerstone Research Group Inc., and…

Heather Cameron, PhD
Senior Vice President, HEOR

As a health economist with over 15 years of experience, Heather has led global health economic and market access programs, as well as local reimbursement projects involving economic modeling, evidence generation, strategy and value communication.…

Nicole Ferko
General Manager, Value and Evidence

Nicole directs U.S. and global projects to support multi-stakeholder medical device adoption and reimbursement. Nicole has more than 20 years of experience in health economics and research methods within academic, industry, and consulting roles.…